CONTRAINDICATIONS
NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

...CONTINUED BELOW

This presentation features the profile of a patient who meets the criteria of severe asthma with an eosinophilic phenotype and is not responding to current therapies. One of the confirmatory clinical studies that evaluated the effect of NUCALA on exacerbations in patients with severe asthma with an eosinophilic phenotype is also discussed.

825656R0 September 2017